Review ArticleReview

G2/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: the old, the new, and the future

Angel Mauricio Castro-Gamero, Julia Alejandra Pezuk, María Sol Brassesco and Luiz Gonzaga Tone
Cancer Biology & Medicine November 2018, 15 (4) 354-374; DOI: https://doi.org/10.20892/j.issn.2095-3941.2018.0030

Article Information

vol. 15 no. 4 354-374
DOI 
https://doi.org/10.20892/j.issn.2095-3941.2018.0030
Published By 
Cancer Biology & Medicine
History 
  • Received February 19, 2018
  • Accepted June 26, 2018
  • Published online November 1, 2018.
Copyright & Usage 
Copyright: © 2018, Cancer Biology & Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Author Information

  1. Angel Mauricio Castro-Gamero⇑1,
  2. Julia Alejandra Pezuk2,
  3. María Sol Brassesco3 and
  4. Luiz Gonzaga Tone4,5
  1. 1Human Genetics Laboratory, Institute of Natural Sciences, Federal University of Alfenas (UNIFAL-MG), Alfenas 37130-001, Brazil
  2. 2Biotechnology and Innovation in Health Program and Pharmacy Program, Anhanguera University São Paulo (UNIAN-SP), São Paulo 05145-200, Brazil
  3. 3Department of Biology, Faculty of Philosophy, Sciences and Letters at Ribeirão Preto, University of São Paulo, Ribeirão Preto 14040-901, Brazil
  4. 4Department of Pediatrics
  5. 5Department of Genetics, Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto 14049-900, Brazil
  1. Correspondence to: Angel Mauricio Castro-Gamero, E-mail: amcgen{at}gmail.com
View Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords